DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity

Seminars in Radiation Oncology

Volumn 25, Issue 4, 2015, Pages 237-250

  Willers, Henning ^a   Gheorghiu, Liliana ^a   Liu, Qi ^a   Efstathiou, Jason A ^a   Wirth, Lori J ^a   Krause, Mechthild ^b,c,d,e   von Neubeck, Cläre ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Helmholtz Zentrum Dresden Rossendorf   (Germany)

^e INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; BRCA1 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FANCONI ANEMIA GROUP D2 PROTEIN; FLUOROURACIL; GAMMA HISTONE H2AX; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RAD51 PROTEIN; TP53 BINDING PROTEIN 1; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CIRCULATING TUMOR CELL; DERMATITIS; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IONIZING RADIATION; LUNG CANCER; NONHUMAN; ORAL MUCOSITIS; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; RECOMBINATION REPAIR; REVIEW; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA; NEOPLASMS; PHYSIOLOGY; RADIATION TOLERANCE;

BIOMARKERS; DNA DAMAGE; HUMANS; NEOPLASMS; RADIATION TOLERANCE;

EID: 84941560295     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2015.05.007     Document Type: Review

References (129)

1. Willers H., Dahm-Daphi J., Powell S.N. Repair of radiation damage to DNA. Br J Cancer 2004, 90(7):1297-1301.
2. Koch U., Höhne K., von Neubeck C., et al. Residual γH2AX foci predict local tumour control after radiotherapy. Radiother Oncol 2013, 108(3):434-439.
3. Ding L., Getz G., Wheeler D.A., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455(7216):1069-1075.
4. Birkelbach M., Ferraiolo N., Gheorghiu L., et al. Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol 2013, 8:279-286.
5. Naipal K.A., Verkaik N.S., Ameziane N., et al. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res 2014, 20(18):4816-4826.
6. Yap K.L., Kiyotani K., Tamura K., et al. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res 2014, 20(24):6605-6617.
7. Alexander B.M., Wang X.Z., Niemierko A., et al. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Int J Radiat Oncol Biol Phys 2011, 83(1):164-171.
8. Patterson M.J., Sutton R.E., Forrest I., et al. Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. Br J Cancer 2014, 111(1):94-100.
9. Lord C.J., Tutt A.N., Ashworth A. Synthetic lethality and cancer therapy: Lessons learned from the development of PARP inhibitors. Annu Rev Med 2015, 66:455-470.
10. Willers H., Pfäffle H.N., Zou L. Targeting Homologous Recombination Repair in Cancer 2012, 119-160. Academic Press, Elsevier. M.R. Kelley (Ed.).
11. Asakawa H., Koizumi H., Koike A., et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res 2010, 12(2):R17.
12. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4(10):814-819.
13. Willers H., Taghian A.G., Luo C.-M., et al. Utility of DNA repair protein foci for the detection of putative BRCA1-pathway defects in breast cancer biopsies. Mol Cancer Res 2009, 7:1304-1309.
14. Mukhopadhyay A., Elattar A., Cerbinskaite A., et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010, 16(8):2344-2351.
15. Goodarzi A.A., Jeggo P.A. Irradiation induced foci (IRIF) as a biomarker for radiosensitivity. Mutat Res 2012, 736(1-2):39-47.
16. Sak A., Stuschke M. Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol 2010, 20(4):223-231.
17. Vignard J., Mirey G., Salles B. Ionizing-radiation induced DNA double-strand breaks: A direct and indirect lighting up. Radiother Oncol 2013, 108(3):362-369.
18. Jalal S., Earley J.N., Turchi J.J. DNA repair: From genome maintenance to biomarker and therapeutic target. Clin Cancer Res 2011, 17(22):6973-6984.
19. Ivashkevich A., Redon C.E., Nakamura A.J., et al. Use of the γH2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett 2012, 327(1-2):123-133.
20. Rogakou E.P., Pilch D.R., Orr A.H., et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273(10):5858-5868.
21. Burma S., Chen B.P., Murphy M., et al. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001, 276(45):42462-42467.
22. Park E.J., Chan D.W., Park J.H., et al. DNA-PK is activated by nucleosomes and phosphorylates H2AX within the nucleosomes in an acetylation-dependent manner. Nucleic Acids Res 2003, 31(23):6819-6827.
23. Ward I.M., Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 2001, 276(51):47759-47762.
24. Rogakou E.P., Boon C., Redon C., et al. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999, 146(5):905-916.
25. Leatherbarrow E.L., Harper J.V., Cucinotta F.A., et al. Induction and quantification of gamma-H2AX foci following low and high LET-irradiation. Int J Radiat Biol 2006, 82(2):111-118.
26. Nakamura A.J., Rao V.A., Pommier Y., et al. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle 2010, 9(2):389-397.
27. Klokov D., MacPhail S.M., Banath J.P., et al. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol 2006, 80(2):223-229.
28. Menegakis A., Yaromina A., Eicheler W., et al. Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining. Int J Radiat Biol 2009, 85(11):1032-1041.
29. Rothkamm K., Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci U S A 2003, 100(9):5057-5062.
30. Kunogi H., Sakanishi T., Sueyoshi N., et al. Prediction of radiosensitivity using phosphorylation of histone H2AX and apoptosis in human tumor cell lines. Int J Radiat Biol 2014, 90(7):587-593.
31. Mahrhofer H., Burger S., Oppitz U., et al. Radiation induced DNA damage and damage repair in human tumor and fibroblast cell lines assessed by histone H2AX phosphorylation. Int J Radiat Oncol Biol Phys 2006, 64(2):573-580.
32. Toulany M., Kehlbach R., Florczak U., et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 2008, 7(7):1772-1781.
33. Fasih A., Elbaz H.A., Huttemann M., et al. Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. Radiat Res 2014, 182(1):50-59.
34. Fokas E., Prevo R., Pollard J.R., et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 2012, 3:e441.
35. Myllynen L., Rieckmann T., Dahm-Daphi J., et al. In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. Radiother Oncol 2011, 101(1):147-151.
36. Wang M., Morsbach F., Sander D., et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 2011, 71(19):6261-6269.
37. Hehlgans S., Storch K., Lange I., et al. The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy. Radiother Oncol 2013, 109(1):126-132.
38. Camphausen K., Burgan W., Cerra M., et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004, 64(1):316-321.
39. Toulany M., Minjgee M., Kehlbach R., et al. ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. Radiother Oncol 2010, 97(2):338-345.
40. Dote H., Burgan W.E., Camphausen K., et al. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res 2006, 66(18):9211-9220.
41. Segawa T., Fujii Y., Tanaka A., et al. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71. Int J Mol Med 2014, 33(3):559-564.
42. Iwasa T., Okamoto I., Suzuki M., et al. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 2009, 15(16):5117-5125.
43. Kriegs M., Kasten-Pisula U., Rieckmann T., et al. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst) 2010, 9(8):889-897.
44. Welsh J.W., Mahadevan D., Ellsworth R., et al. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 2009, 4:69.
45. Hayman T.J., Wahba A., Rath B.H., et al. The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells. Clin Cancer Res 2014, 20(1):110-119.
46. Chen H., Ma Z., Vanderwaal R.P., et al. The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat Res 2011, 175(2):214-224.
47. Shelton J.W., Waxweiler T.V., Landry J., et al. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys 2013, 86(3):469-476.
48. Fokas E., Yoshimura M., Prevo R., et al. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol 2012, 27(7):48.
49. Kao G.D., Jiang Z., Fernandes A.M., et al. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 2007, 282(29):21206-21212.
50. Raju U., Riesterer O., Wang Z.Q., et al. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol 2012, 105(2):241-249.
51. Zhang C., Yang X., Zhang Q., et al. STAT3 inhibitor NSC74859 radiosensitizes esophageal cancer via the downregulation of HIF-1alpha. Tumour Biol 2014, 35(10):9793-9799.
52. Zhang M., Kleber S., Rohrich M., et al. Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011, 71(23):7155-7167.
53. PosthumaDeBoer J., Wurdinger T., Graat H.C., et al. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 2011, 11:156.
54. Bonner W.M., Redon C.E., Dickey J.S., et al. GammaH2AX and cancer. Nat Rev Cancer 2008, 8(12):957-967.
55. Bourton E.C., Plowman P.N., Smith D., et al. Prolonged expression of the γH2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radiotherapy treatment. Int J Cancer 2011, 129(12):2928-2934.
56. Markova E., Schultz N., Belyaev I.Y. Kinetics and dose-response of residual 53BP1/gamma-H2AX foci: Co-localization, relationship with DSB repair and clonogenic survival. Int J Radiat Biol 2007, 83(5):319-329.
57. Xiong X., Du Z., Wang Y., et al. 53BP1 promotes microhomology-mediated end-joining in G1-phase cells. Nucleic Acids Res 2015, 43(3):1659-1670.
58. Kakarougkas A., Ismail A., Klement K., et al. Opposing roles for 53BP1 during homologous recombination. Nucleic Acids Res 2013, 41(21):9719-9731.
59. Solier S., Pommier Y. The apoptotic ring: A novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinases. Cell Cycle 2009, 8(12):1853-1859.
60. Sirbu B.M., Couch F.B., Feigerle J.T., et al. Analysis of protein dynamics at active, stalled, and collapsed replication forks. Genes Dev 2011, 25(12):1320-1327.
61. Djuzenova C.S., Elsner I., Katzer A., et al. Radiosensitivity in breast cancer assessed by the histone γH2AX and 53BP1 foci. Radiat Oncol 2013, 8:98.
62. Lassmann M., Hanscheid H., Gassen D., et al. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2010, 51(8):1318-1325.
63. Cornelissen B., Kersemans V., Darbar S., et al. Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates. Cancer Res 2011, 71(13):4539-4549.
64. Yuan S.S., Lee S.Y., Chen G., et al. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999, 59(15):3547-3551.
65. Zhang J., Willers H., Feng Z., et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004, 24(2):708-718.
66. Saleh-Gohari N., Bryant H.E., Schultz N., et al. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005, 25(16):7158-7169.
67. Digweed M., Rothe S., Demuth I., et al. Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis 2002, 23(7):1121-1126.
68. Godthelp B.C., Wiegant W.W., Waisfisz Q., et al. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res 2006, 594(1-2):39-48.
69. Garcia-Higuera I., Taniguchi T., Ganesan S., et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7(2):249-262.
70. Tebbs R.S., Hinz J.M., Yamada N.A., et al. New insights into the Fanconi anemia pathway from an isogenic FancG hamster CHO mutant. DNA Repair (Amst) 2005, 4(1):11-22.
71. Willers H., Kachnic L.A., Luo C.-M., et al. Biomarkers and mechanisms of FANCD2 function. J Biomed Biotechnol 2008, 821529.
72. Scully R., Chen J., Plug A., et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88(2):265-275.
73. Scully R., Chen J., Ochs R.L., et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997, 90(3):425-435.
74. Huen M.S., Sy S.M., Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010, 11(2):138-148.
75. Scully R., Ganesan S., Vlasakova K., et al. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999, 4:1093-1099.
76. Shi W., Ma Z., Willers H., et al. Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation. J Biol Chem 2008, 283(46):31608-31616.
77. Nakanishi K., Yang Y.G., Pierce A.J., et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A 2005, 102(4):1110-1115.
78. Kuhnert V.M., Kachnic L.A., Li L., et al. FANCD2-deficient human fibroblasts are hypersensitive to ionising radiation at oxygen concentrations of 0% and 3% but not under normoxic conditions. Int J Radiat Biol 2009, 85(6):523-531.
79. Wilson J.B., Blom E., Cunningham R., et al. Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance. Mutat Res 2010, 689(1-2):12-20.
80. Wilson J.B., Yamamoto K., Marriott A.S., et al. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene 2008, 27(26):3641-3652.
81. Kennedy R.D., D'Andrea A.D. DNA repair pathways in clinical practice: Lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006, 24(23):3799-3808.
82. Chan D.W., Chen B.P., Prithivirajsingh S., et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 2002, 16(18):2333-2338.
83. Wang X., Andreassen P.R., D'Andrea A.D. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004, 24(13):5850-5862.
84. Tarsounas M., Davies D., West S.C. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene 2003, 22(8):1115-1123.
85. Powell S.N., Kachnic L.A. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 2008, 8(4):448-460.
86. Gahwiler B.H., Capogna M., Debanne D., et al. Organotypic slice cultures: A technique has come of age. Trends Neurosci 1997, 20(10):471-477.
87. Noraberg J., Poulsen F.R., Blaabjerg M., et al. Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair. Curr Drug Targets CNS Neurol Disord 2005, 4(4):435-452.
88. Merz F., Gaunitz F., Dehghani F., et al. Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol 2013, 15(6):670-681.
89. Vaira V., Fedele G., Pyne S., et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A 2010, 107(18):8352-8356.
90. Pfaffle H.N., Wang M., Gheorghiu L., et al. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res 2013, 73(20):6254-6263.
91. Garcia-Villa A., Balasubramanian P., Miller B.L., et al. Assessment of γH2AX levels in circulating tumor cells from patients receiving chemotherapy. Front Oncol 2012, 2:128.
92. Kummar S., Chen A., Ji J., et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011, 71(17):5626-5634.
93. Kummar S., Ji J., Morgan R., et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012, 18(6):1726-1734.
94. Wang L.H., Pfister T.D., Parchment R.E., et al. Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010, 16(3):1073-1084.
95. Ilie M., Hofman V., Long E., et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?. Ann Transl Med 2014, 2(11):107.
96. Koch U., Krause M., Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures-Radiation oncology perspective. Semin Cancer Biol 2010, 20(2):116-124.
97. Olive P.L., Banath J.P. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 2004, 58(2):331-335.
98. Banuelos C.A., Banath J.P., Kim J.Y., et al. gammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin Cancer Res 2009, 15(10):3344-3353.
99. Olive P.L., Banuelos C.A., Durand R.E., et al. Endogenous and radiation-induced expression of gammaH2AX in biopsies from patients treated for carcinoma of the uterine cervix. Radiother Oncol 2010, 94(1):82-89.
100. Hoffmann T.K. Systemic therapy strategies for head-neck carcinomas: Current status. GMS Curr Top Otorhinolaryngol Head Neck Surg 2012, 11. [Doc03].
101. Menegakis A., Eicheler W., Yaromina A., et al. Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. Radiother Oncol 2011, 100(1):137-144.
102. Yaromina A., Thames H., Zhou X., et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol 2010, 96(1):116-122.
103. Yaromina A., Eckardt A., Zips D., et al. Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies. Radiother Oncol 2009, 92(3):460-465.
104. Krause M., Yaromina A., Eicheler W., et al. Cancer stem cells: Targets and potential biomarkers for radiotherapy. Clin Cancer Res 2011, 17(23):7224-7229.
105. Jamal M., Rath B.H., Tsang P.S., et al. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia 2012, 14(2):150-158.
106. Mumbrekar K.D., Fernandes D.J., Goutham H.V., et al. Influence of double-strand break repair on radiation therapy-induced acute skin reactions in breast cancer patients. Int J Radiat Oncol Biol Phys 2013, 88(3):671-676.
107. Sak A., Grehl S., Engelhard M., et al. Long-term in vivo effects of cisplatin on gamma-H2AX foci signaling in peripheral lymphocytes of tumor patients after irradiation. Clin Cancer Res 2009, 15(8):2927-2934.
108. Wyatt M.D., Wilson D.M. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009, 66(5):788-799.
109. Fleckenstein J., Kuhne M., Seegmuller K., et al. The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011, 81(5):1465-1472.
110. Liu Q., Ghosh P., Magpayo N., et al. Lung cancer cell line screen links Fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation. Int J Radiat Oncol Biol Phys 2015, 91(5):1081-1089.
111. Graeser M., McCarthy A., Lord C.J., et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010, 16(24):6159-6168.
112. Shah M.M., Dobbin Z.C., Nowsheen S., et al. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol 2014, 134(2):331-337.
113. Kumareswaran R., Ludkovski O., Meng A., et al. Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. J Cell Sci 2012, 125(Pt 1):189-199.
114. Bindra R.S., Schaffer P.J., Meng A., et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004, 24(19):8504-8518.
115. Sedelnikova O.A., Bonner W.M. GammaH2AX in cancer cells: A potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006, 5(24):2909-2913.
116. Wu J., Clingen P.H., Spanswick V.J., et al. γH2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: Results from 2 phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res 2013, 19(3):721-730.
117. Park J.W., Nickel K.P., Torres A.D., et al. Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. Radiother Oncol 2014, 113(3):337-344.
118. Rieckmann T., Tribius S., Grob T.J., et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol 2013, 107(2):242-246.
119. Lohaus F., Linge A., Tinhofer I., et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2014, 113(3):317-323.
120. Bhogal N., Jalali F., Bristow R.G. Microscopic imaging of DNA repair foci in irradiated normal tissues. Int J Radiat Biol 2009, 85(9):732-746.
121. Redon C.E., Weyemi U., Parekh P.R., et al. γH2AX and other histone post-translational modifications in the clinic. Biochim Biophys Acta 2012, 1819(7):743-756.
122. Sak A., Grehl S., Erichsen P., et al. gamma-H2AX foci formation in peripheral blood lymphocytes of tumor patients after local radiotherapy to different sites of the body: Dependence on the dose-distribution, irradiated site and time from start of treatment. Int J Radiat Biol 2007, 83(10):639-652.
123. Goutham H.V., Mumbrekar K.D., Vadhiraja B.M., et al. DNA double-strand break analysis by γH2AX foci: A useful method for determining the overreactors to radiation-induced acute reactions among head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2013, 84(5):e607-e612.
124. Rübe C.E., Fricke A., Schneider R., et al. DNA repair alterations in children with pediatric malignancies: Novel opportunities to identify patients at risk for high-grade toxicities. Int J Radiat Oncol Biol Phys 2010, 78(2):359-369.
125. Schuler N., Palm J., Kaiser M., et al. DNA-damage foci to detect and characterize DNA repair alterations in children treated for pediatric malignancies. PLoS One 2014, 9(3):e91319.
126. van Oorschot B., Hovingh S.E., Moerland P.D., et al. Reduced activity of double-strand break repair genes in prostate cancer patients with late normal tissue radiation toxicity. Int J Radiat Oncol Biol Phys 2014, 88(3):664-670.
127. Brzozowska K., Pinkawa M., Eble M.J., et al. In vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy. Int J Radiat Biol 2012, 88(5):405-413.
128. Werbrouck J., Duprez F., De Neve W., et al. Lack of a correlation between γH2AX foci kinetics in lymphocytes and the severity of acute normal tissue reactions during IMRT treatment for head and neck cancer. Int J Radiat Biol 2011, 87(1):46-56.
129. Liu Q., Wang M., Kern A.M., et al. Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. Mol Cancer Res 2015, 13(4):713-720.